Market Overview

Ariad Shares Continue to Surge Amidst Buyout Rumors


Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) continue to surge following commercial availability of Iclusig and the UK Daily Mail's report on a potential buyout.

On January 17, Ariad reported on the commercial availability of Iclusig^® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. Following the FDA approval, the UK Daily Mail reported that at least three international big pharma companies have approached Ariad regarding a potential buyout. The pharma companies include Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc (NYSE: GSK), and Shire plc (NASDAQ: SHPG) who are rumored to pay as much as $20.00 per share.

BMO Capital Markets analyst Jim Birchenough commented that Ariad has “significant value” to be realized from Iclusig. Birchenough raised his rating from Market Perform to Outperform and increased the price target from $8.00 to $14.00. Ariad told BMO that “all options, including partnership and M&A” remain on the table. The analyst added that commercializing Iclusig would require additional funding, to expand the drug beyond the narrow label.

Shares of Ariad Pharmaceuticals is up as much as 15% following the Daily Mail's article. Ariad closed at $8.98 on Friday, up 19.41% for the day.

Latest Ratings for ARIA

Jan 2017DowngradesBuyHold
Jan 2017UpgradesUnderweightEqual-Weight
Jan 2017DowngradesBuyHold

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Rumors Price Target Offerings FDA Analyst Ratings


Related Articles (ARIA + GSK)

View Comments and Join the Discussion!

Latest Ratings

MSB of A SecuritiesReiterates62.0
ZEALMorgan StanleyMaintains38.0
RAREMorgan StanleyMaintains77.0
SGENMorgan StanleyMaintains115.0
RGNXMorgan StanleyMaintains58.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at